East China’s Jiangsu province has taken multiple measures in recent years to accelerate the development and growth of science and technology enterprises, promoting new momentum for high-quality development.
Located in Jiangning High-tech Zone, Nanjing, the new drug "Cidaki Orenza" independently developed by Legend Bio for the treatment of multiple myeloma has been approved by the US FDA for marketing, marking the successful launch of China's first innovative CAR-T drug.
Thanks to the original technical route, the innovative drug has remarkable curative effect and obtained the first "breakthrough therapy" certification in the history of China's State Food and Drug Administration.
Fan Xiaohu, Chief Scientific Officer of Legend Bio
In a clinical trial of 97 patients
98% of the patients had
meaningful and measurable clinical efficacy
and 83% of the patients
achieved complete remission
in a two-year follow-up
This is a very rare high response rate
in the history of tumor drug development
The drug is the first innovative drug Legend Bio has developed since its inception 7 years ago. The successful development is inseparable from the policy support given by the science and technology department, in particular nearly 30 million yuan of technological funding support in various projects.
Kong Zhengyu, Director of Public Affairs Department of Legend Bio
These project support policies
have not only relieved the huge financial pressure
faced by the company in the early stage
of research and development
but more importantly
greatly mobilized and improved the enthusiasm
of the company's scientific research personnel
and encouraged and stimulated
the company's enthusiasm for independent innovation
High-tech enterprises in Jiangsu undertake 80% of the provincial scientific and technological achievements transformation projects and 60% of the provincial key R&D plan projects, and through project support, help enterprises to cross the "valley of death" from "scientific research achievements" to "innovative products".
In order to further strengthen the source of innovation for enterprises, Jiangsu has also set up a high-tech enterprise cultivation library and given three-year cultivation rewards.
Banks have issued "Jiangsu Science and Technology Loans" of 69 billion yuan to support more than 7,300 technology-based small, medium and micro enterprises
Jiangsu has introduced policies to support high-tech enterprises to enjoy preferential corporate income tax. In 2020 alone, local enterprises were granted corporate income tax reduction of more than 35 billion yuan.
Up to now, the province has more than 37,000 high-tech enterprises, ranking second in the country.
Zhang Hua, Vice President of Jiangsu Academy of Science and Technology Development Strategy
The global layout of new R&D institutions
the full-cycle support
of preferential tax policies
for science and technology
and the comprehensive deepening of policies
for the transformation
of scientific and technological achievements
have escorted the innovation
of scientific and technological enterprises
The group-type and explosive development
of science and technology enterprises
has built a solid foundation
for Jiangsu to continue
to absorb high-level employment
develop high-quality economy
and cope with multiple risks
